Furthermore, SETD2 expression levels positively correlated with progression of disease as levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died of breast cancer when compared to those who were disease free for > 10 years (p = 0.041) (median follow up 120 months). Here, SETD2 is linked to breast cancer.